Reversible relapse of pemphigus foliaceus triggered by topical imiquimod suggests that Toll-like receptor 7 inhibitors may be useful treatments for pemphigus

Clinical and Experimental Dermatology

Volumn 36, Issue 1, 2011, Pages 91-93

  Sebaratnam, D F ^a,b   Martin, L K ^a   Rubin, A I ^a,d   Tran, K ^b   Pas, H H ^a,e   Marr, P J ^c   Edmonds, J ^f   Murrell, D F ^a,b  

^a SEALS   (Australia)

^b Division of Anatomical Pathology   (Australia)

^c ST GEORGE HOSPITAL   (Australia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPTOPRIL; FLUOROURACIL; IMIQUIMOD; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; MOMETASONE FUROATE; NIFEDIPINE; PENICILLAMINE; PIROXICAM; PREDNISONE; PROPRANOLOL; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

ADULT; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KERATINOCYTE; LETTER; PEMPHIGUS FOLIACEUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUNCH BIOPSY; RELAPSE; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AMINOQUINOLINES; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MIDDLE AGED; PEMPHIGUS; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 7; TREATMENT OUTCOME;

EID: 78650160681     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2010.03918.x     Document Type: Letter

References (9)

1. Murrell DF, Dick S, Ahmed AR et al. Consensus statement on definitions of disease, end points and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.
2. Lin R, Ladd DJ Powell DJ et al. Localized pemphigus foliaceus induced by topical imiquimod. Arch Dermatol 2004; 140: 889-90.
3. Lo Shiavo A, Sangiuliano S, Puca RV. Contact pemphigus: a side-effect of imiquimod therapy. Int J Dermatol 2008; 47: 765-7.
4. Champagne G, Roca M, Martinez A. Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. Eur J Obstet Gynecol Reprod Biol 2003; 109: 224-7.
5. Sauder DN. Immunomodulatory and pharmacological properties of imiquimod. J Am Acad Dermatol 2000; 43: S6-11.
6. Wu P, Wu J Liu S et al. TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin Immunol 2008; 129: 40-8.
7. Fleischmann M, Célérier P Bernard P et al. Long-term interferon-alpha therapy induces autoantibodies against epidermis. Dermatology 1996; 192: 50-5.
8. Mashiah J, Brenner S. Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod therapy. Arch Dermatol 2005; 141: 908.
9. Barrat FJ, Meeker T, Chan JH et al. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 2007; 37: 3582-6.